# data[].attributes.body
Paget's Disease of Bone was interesting to learn about in the context of archaeological findings. Bones showing symptoms of PDB date back to 900-1850 in Northern England, and I find it fascinating that evidence of this disease can be traced back so far in time. It surprised me to learn that this is the second most common bone remodeling disease after osteoporosis. While a fair amount of patients can be asymptomatic, it was surprising to learn that the disease was quite common given that treatments are relatively new. Had I chosen a disease that was spread by being airborne or through contact of sorts, I believe the Padlet assignment topics would have made more sense. As PDB is genetic, talking about disease spread or societal effects was not as relevant.

# data[].attributes.body
When Sir James Paget recognized Paget's bone disease for what it was over 130 years ago, it was nothing novel. PDB is the second most common bone remodeling disease after osteoporosis. While many patients with PDB are asymptomatic, the disease can affect just one or many bones. The impact of recognizing the disease paved a way for treatments. While societal behavions did not change, the science world began to work on treatments. In the 70's the first calcitonin treatment was developed, and in recent years a newer, more effective bisphosphonate treatment was found. Society did not so much as learn for the physical effects of the disease as they did put a name to a problem.

# data[].attributes.body
As PDB is a genetic disease rather than a quickly spreading virus, the disease was and still is mainly handled by doctors. PDB was given a name over 130 years ago but did not just occur; evidence of bone deformations has been found in countless archaeological remains. Now, the disease can be confirmed in a patient via x-ray or biochemical marker serum, and all who present PDB are recommended treatment.
A new treatment using amino-bisphosphonates was recently developed to combat PDB. It has so far proven effective in bone and joint pain reduction. Should a patient have a less severe form of PDB, nonspecific anti-inflammatories are also known to work well.
In response to a disease that has most likely always been around, I believe that leadership (in the form of doctors and scientists) has been working to progress research in the field of providing treatment for PDB. It is possible that eventually the genes that code for PDB can be recognized and removed earlier in life before symptoms arise, but as of now, the research going into pain reduction for patients has seen lots of good progress.

# data[].attributes.body
Being that PDB is the second most common bone remodeling disease, the healthcare community is familiar with the disease. In most cases, symptoms will begin well after 40 years of age and in all such cases treatments are recommended.
In the 1970s an injectable treatment with calcitonin was developed. It along with 6 others were approved by the FDA. The calcitonin treatment specifically is associated with lessening bone pains, healing bone lesions, and improving any neurological complications. Nonspecific therapies such as acetaminophen, aspirin, and anti-inflammatory drugs can also aid in degenerative joint diseases and bone pains.
More recently, a very effective treatment using potent amino-bisphosphonates has been developed and is associated with significantly decreasing bone and joint pains. This treatment can be taken both orally and intravenously; however, the oral dose has been linked to upper GI problems most of which can be combated with acetaminophen.

# data[].attributes.body
Virulence can be defined as the harm done by a pathogen to the host following infection.
While PDB can be asymptomatic, the severity of the disease ranges depending on the complications a patient presents - these complications include musculoskeletal, cardiovascular, neurologic, neoplastic, etc. PDB involves one or more bones being affected, however, it is unusual for a new bone to become involved after the initial diagnosis.

# data[].attributes.body
By analyzing archaeological skeletons dating back to 900-1850 in Northern England, 2.1% of analyzed remains older than 40 years had PDB. Before 1500, the prevalence of PDB was approximately 1.7% and reached 3.1% after 1500. PDB is most common in the UK and Western Europe but had shown a decrease in incidence in the last 25-30 years. This map shows locations in the UK with a high prevalence of PDB in the late 1970s and early 1980s. Of the 1000 skeletal remains found at an excavation site in Barton, 667 bones met the original criteria leading to 15 cases of PDB being diagnosed. 7 cases came from before 1500 and 8 cases from after 1500.

https://doi.org/10.1359/jbmr.2002.17.6.1127

# data[].attributes.body
Paget's disease of bone (PDB) was first detected in 1877 by Sir James Paget who thought it was an inflammatory process that was causing bone malformation.
It was first suspected that the infectious agent was the measles virus; however, recent studies more strongly support an association between PDB and a vitamin D deficiency.
PDB is a metabolic bone disease of the osteoclasts; there is an increase in bone resorption followed by the unregulated formation of bone. Both genetic and environmental factors contribute to the development of PDB. If PDB is a result of a vitamin D deficiency, it would be considered a deficiency disease.

# data[].attributes.body
Paget's disease of bone is also known as osteitis deformans. This disease is a common bone remodeling disorder discovered by Sir James Paget in 1877.